Kura Oncology Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Kura Oncology de 39.5% y 40.5% respectivamente, mientras que el BPA crecerá en un 40.8% al año.

Información clave

39.5%

Tasa de crecimiento de los beneficios

40.81%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.6%
Tasa de crecimiento de los ingresos	40.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	23 May 2025

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates

May 04

Recent updates

Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates

May 07

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates

May 04

NDA Submission And Trial Progress Will Forge Market Opportunities

Mar 27 Successful NDA submission and accelerated approval paths could enable early market entry, boosting future revenues and earnings.

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Mar 04

Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62%

Mar 04

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Jun 26

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Nov 23

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Aug 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:KURA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2027	285	-145	-111	-73	11
12/31/2026	204	-158	13	68	14
12/31/2025	161	-143	27	-178	13
3/31/2025	68	-182	111	111	N/A
12/31/2024	54	-174	134	134	N/A
9/30/2024	N/A	-198	-169	-169	N/A
6/30/2024	N/A	-182	-155	-155	N/A
3/31/2024	N/A	-168	-138	-138	N/A
12/31/2023	N/A	-153	-125	-125	N/A
9/30/2023	N/A	-143	-117	-117	N/A
6/30/2023	N/A	-140	-110	-109	N/A
3/31/2023	N/A	-137	-114	-114	N/A
12/31/2022	N/A	-136	-111	-110	N/A
9/30/2022	N/A	-135	-108	-107	N/A
6/30/2022	N/A	-133	-112	-110	N/A
3/31/2022	N/A	-132	-109	-108	N/A
12/31/2021	N/A	-130	-106	-105	N/A
9/30/2021	N/A	-124	-101	-99	N/A
6/30/2021	N/A	-114	-93	-92	N/A
3/31/2021	N/A	-101	-80	-79	N/A
12/31/2020	N/A	-90	-72	-70	N/A
9/30/2020	N/A	-81	-67	-65	N/A
6/30/2020	N/A	-74	-62	-61	N/A
3/31/2020	N/A	-68	-61	-60	N/A
12/31/2019	N/A	-63	-55	-55	N/A
9/30/2019	N/A	-61	-51	-51	N/A
6/30/2019	N/A	-60	-52	-52	N/A
3/31/2019	N/A	-60	-50	-50	N/A
12/31/2018	N/A	-60	N/A	-49	N/A
9/30/2018	N/A	-55	N/A	-46	N/A
6/30/2018	N/A	-49	N/A	-39	N/A
3/31/2018	N/A	-43	N/A	-33	N/A
12/31/2017	N/A	-35	N/A	-28	N/A
9/30/2017	N/A	-32	N/A	-28	N/A
6/30/2017	N/A	-30	N/A	-27	N/A
3/31/2017	N/A	-28	N/A	-27	N/A
12/31/2016	N/A	-28	N/A	-25	N/A
9/30/2016	N/A	-27	N/A	-24	N/A
6/30/2016	N/A	-26	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-21	N/A
12/31/2015	N/A	-23	N/A	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que KURA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que KURA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que KURA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (40.5% al año) de KURA crezcan más rápidamente que los del mercado US (8.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (40.5% al año) de KURA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de KURA se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/05/28 14:10
Precio de las acciones al final del día	2025/05/28 00:00
Beneficios	2025/03/31
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Kura Oncology, Inc. está cubierta por 20 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Peter Lawson	Barclays
Jason Zemansky	BofA Global Research
Leah Rush Cann	Brookline Capital Markets

Kura Oncology Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 20%

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 51%, EPS downgraded

Price target decreased by 10% to US$28.46

Price target decreased to US$32.67

Price target decreased to US$38.43

Recent updates

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation At the 2025 European Hematology Association (Eha) Congress

Consensus revenue estimates increase by 20%

Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Boosting Their Estimates

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Kura Oncology, Inc. to Report Q1, 2025 Results on May 01, 2025

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2025

Kura Oncology, Inc. Announce Submission of New Drug Application for Ziftomenib to FDA

NDA Submission And Trial Progress Will Forge Market Opportunities

Lead Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 51%, EPS downgraded

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62%

Kura Oncology, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

New minor risk - Insider selling

Kura Oncology: Sentiment Is Too Negative

Kura Oncology, Inc. Announces Senior Executive Promotions

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting

New minor risk - Share price stability

Kura Oncology: A Contender In The Field Of Precision Medicine

Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology: The Long Holding Pattern Is Risky

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Estimating The Fair Value Of Kura Oncology, Inc. (NASDAQ:KURA)

Now 20% undervalued after recent price drop

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Now 21% overvalued after recent price rise

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology: Balancing Act Of Promise And Pragmatism

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology: Ziftomenib's Path To AML Market Widens

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Chairman notifies of intention to sell stock

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

New minor risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Price target decreased by 10% to US$28.46

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold US$61k worth of stock

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$32.67

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating